• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Synergy CHC Corp. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    6/29/26 4:15:26 PM ET
    $SNYR
    Other Pharmaceuticals
    Health Care
    Get the next $SNYR alert in real time by email
    false 0001562733 0001562733 2026-06-29 2026-06-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the

    Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): June 29, 2026

     

    SYNERGY CHC CORP.

    (Exact name of registrant as specified in its charter)

     

    Nevada   001-42374   99-0379440
    (State or Other Jurisdiction   (Commission File Number)   (IRS Employer
    of Incorporation)       Identification No.)

     

    770 Roosevelt Trail STE 8 #1016, N. Windham, Maine   04062
    (Address of principal executive offices)   (Zip Code)

     

    Registrant’s telephone number, including area code: (207) 321-2350

     

    N/A

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common Stock, par value $0.00001 per share   SNYR   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR § 230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR § 240.12b-2).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

      

     

     

     

     

    Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

     

    On June 29, 2026, Synergy CHC Corp. (the “Company”) held its 2026 annual meeting of stockholders (the “Annual Meeting”). As further discussed below, at the Annual Meeting, the Company’s stockholders approved a proposal to amend (the “Amendment”) the Synergy CHC Corp. 2024 Equity Incentive Plan (the “2024 Plan”) to (i) increase the aggregate number of shares of the Company’s common stock, par value $0.00001 per share (“Common Stock”), available for issuance under the 2024 Plan to 150,000,000 shares of Common Stock and (ii) permit repricing of outstanding awards. There were no other changes to the 2024 Plan. The board of directors of the Company had previously approved the Amendment on April 17, 2026.

     

    The summary of the Amendment contained herein does not purport to be complete and is qualified in its entirety by reference to the full text of the Amendment, which is filed as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated by reference herein.

     

    The disclosure set forth below in Item 5.07 of this Current Report on Form 8-K is incorporated by reference into this Item 5.02.

     

    Item 5.07. Submission of Matters to a Vote of Security Holders.

     

    Summary of Proposals Submitted to Stockholders

     

    At the Annual Meeting, the following proposals were submitted to the stockholders of the Company, as set forth in the Company’s definitive proxy statement for the 2026 Annual Meeting filed with the Securities and Exchange Commission on April 30, 2026:

     

    Proposal 1: The election of five (5) directors, each to serve until the 2027 annual meeting of stockholders.
       
    Proposal 2: The ratification of the appointment of RBSM LLP (“RBSM”) as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
       
    Proposal 3: The approval of an amendment to the 2024 Plan to (i) increase the number of shares of Common Stock available for issuance under the 2024 Plan to 150,000,000 shares and (ii) permit repricing of outstanding awards.
       
    Proposal 4: The approval of the full issuance of shares of common stock issuable by the Company upon exercise of the Lender Warrant for purposes of complying with Nasdaq Listing Rules 5635(b) and 5635(d).
       
    Proposal 5: The approval of one or more reverse stock splits of our issued and outstanding shares of Common Stock at one or more specific ratios to be determined by the Board, provided that the aggregate ratio of all such reverse stock splits does not exceed 1-for-200.

     

    Voting Results

     

    On April 24, 2026 (the “Record Date”), there were 14,899,883 shares of Common Stock outstanding and entitled to vote. Of the 14,899,883 votes that were eligible to be cast by the holders of Common Stock at the Annual Meeting, 9,808,119 votes, or approximately 65% of the total, were represented at the Annual Meeting virtually or by proxy, constituting a quorum. The number of votes cast for, against or withheld, as well as abstentions and broker non-votes, if applicable, in respect of each such matter is set forth below:

     

    1

     

     

    Proposal 1: Election of Directors.

     

    The Company’s stockholders elected the following directors to serve until the 2027 annual meeting of stockholders. The votes regarding the election of these directors were as follows:

     

    Director Nominee  Votes For   Votes
    Withheld
       Broker
    Non-Votes
     
    Alfred Baumeler   7,184,954    466,393    2,156,772 
    Nitin Kaushal   7,176,292    475,055    2,156,772 
    Jack Ross   7,183,853    467,494    2,156,772 
    J. Paul SoRelle   7,183,937    467,410    2,156,772 
    Teresa Thompson   7,180,349    470,998    2,156,772 

     

    Proposal 2: Ratification of the Appointment of RBSM.

     

    The Company’s stockholders ratified the appointment of RBSM as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The votes regarding this proposal were as follows:

     

    Votes For

      Votes Against   Abstentions   Broker Non-Votes
    9,808,117   472,432   13,197   -

     

    Proposal 3: Proposed Amendment to the 2024 Plan.

     

    The Company’s stockholders approved the proposal to amend the 2024 Plan to (i) increase the number of shares of Common Stock available for issuance under the 2024 Plan to 150,000,000 shares and (ii) permit repricing of outstanding awards. The votes regarding this proposal were as follows:

     

    Votes For

      Votes Against   Abstentions   Broker Non-Votes
    6,782,598   860,297   8,451   2,156,773

     

    2

     

     

    Proposal 4: Proposed Issuance of Shares of Common Stock.

     

    The Company’s stockholders approved the proposal regarding the full issuance of shares of common stock issuable by the Company upon exercise of the Lender Warrant for purposes of complying with Nasdaq Listing Rules 5635(b) and 5635(d). The votes regarding this proposal were as follows:

     

    Votes For

      Votes Against   Abstentions   Broker Non-Votes
    7,327,670   301,715   21,961   2,156,772

     

    Proposal 5: Proposed Reverse Stock Split.

     

    The Company’s stockholders approved the proposal to approve one or more reverse stock splits of our issued and outstanding shares of Common Stock at one or more specific ratios to be determined by the Board, provided that the aggregate ratio of all such reverse stock splits does not exceed 1-for-200. The votes regarding this proposal were as follows:

     

    Votes For

      Votes Against   Abstentions   Broker Non-Votes
    8,827,762   969,208   11,148   -

     

    Item 9.01. Financial Statements and Exhibits.

     

    (d) Exhibits.

     

    Exhibit No.   Description
    10.1   Amendment No. 3 to Synergy CHC Corp. 2024 Equity Incentive Plan
    104   Cover Page Interactive Data File (formatted in Inline XBRL).

     

    3

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: June 29, 2026    
         
      SYNERGY CHC CORP.
         
      By: /s/ Jack Ross
      Name:  Jack Ross
      Title: Chief Executive Officer

     

    4

     

    Get the next $SNYR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SNYR

    DatePrice TargetRatingAnalyst
    2/2/2026$5.00Buy
    Ascendiant Capital Markets
    1/21/2025$10.00Buy
    ROTH MKM
    More analyst ratings

    $SNYR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Synergy CHC Corp. Reports First Quarter 2026 Financial Results

    N. WINDHAM, Maine, May 14, 2026 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ:SNYR) ("Synergy" or the "Company"), a consumer health and wellness company, is announcing its financial results for the three months ended March 31, 2026. "Our first quarter results reflect continued execution and the growing momentum of our functional beverage business," said Jack Ross, CEO of Synergy CHC Corp. "During the quarter, we generated over $650,000 in functional beverage revenue, exceeding our total beverage revenue for all of 2025. This performance reflects the success of our expanding retail and distribution partnerships across the U.S., supported by healthy sell-through that is already driving incr

    5/14/26 8:00:00 AM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    Synergy CHC Corp. Reports Fourth Quarter and Full Year 2025 Financial Results

    NORTH WINDHAM, Maine, April 01, 2026 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ:SNYR) ("Synergy" or the "Company"), a consumer health and wellness company, is announcing its financial results for the three and twelve months ended December 31, 2025. "Our full year results reflect a year of meaningful strategic progress and continued advancement of our priority growth initiatives," said Jack Ross, CEO of Synergy CHC Corp. "During 2026 on the beverage side, we have shipped our Focus and Energy RTDs and shots into several new key distribution partners, including EG America, Wakefern Food, and Pine State Beverage, to name a few. With millions of cans of RTDs and shots in stock and ready to

    4/1/26 8:00:00 AM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    Synergy CHC Corp. Announces Date Change of Fourth Quarter and Full Year 2025 Earnings and Conference Call

    WESTBROOK, Maine, March 30, 2026 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ:SNYR) ("Synergy" or the "Company"), a leading consumer health and wellness company, today announced an updated date for the release of its fourth quarter and full year financial results ended December 31, 2025. The Company will now report its financial results on Wednesday, April 1, 2026, before the open of market trading. In conjunction with reporting fourth quarter and full year 2025 results, Synergy will host a conference call at 9:00 a.m. ET / 6:00 a.m. PT with the Company's Chief Executive Officer, Jack Ross, and the Company's Chief Financial Officer, Jaime Fickett. A live webcast of the call will be avail

    3/30/26 5:14:41 PM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    $SNYR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Ascendiant Capital Markets initiated coverage on Synergy CHC Corp. with a new price target

    Ascendiant Capital Markets initiated coverage of Synergy CHC Corp. with a rating of Buy and set a new price target of $5.00

    2/2/26 6:52:55 AM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    ROTH MKM initiated coverage on Synergy CHC Corp. with a new price target

    ROTH MKM initiated coverage of Synergy CHC Corp. with a rating of Buy and set a new price target of $10.00

    1/21/25 9:10:17 AM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    $SNYR
    SEC Filings

    View All

    Synergy CHC Corp. filed SEC Form 8-K: Leadership Update, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - Synergy CHC Corp. (0001562733) (Filer)

    6/29/26 4:15:26 PM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    SEC Form EFFECT filed by Synergy CHC Corp.

    EFFECT - Synergy CHC Corp. (0001562733) (Filer)

    5/26/26 12:15:25 AM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    Synergy CHC Corp. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - Synergy CHC Corp. (0001562733) (Filer)

    5/18/26 9:01:37 AM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    $SNYR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    CEO and Chairman Ross Jack bought $79,578 worth of shares (27,900 units at $2.85), increasing direct ownership by 7% to 410,507 units (SEC Form 4)

    4 - Synergy CHC Corp. (0001562733) (Issuer)

    7/31/25 8:31:46 AM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    CEO and Chairman Ross Jack bought $29,837 worth of shares (16,100 units at $1.85), increasing direct ownership by 4% to 382,607 units (SEC Form 4)

    4 - Synergy CHC Corp. (0001562733) (Issuer)

    6/11/25 7:17:28 PM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    CEO and Chairman Ross Jack bought $10,870 worth of shares (5,300 units at $2.05), increasing direct ownership by 1% to 366,507 units (SEC Form 4)

    4 - Synergy CHC Corp. (0001562733) (Issuer)

    5/21/25 5:05:31 PM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    $SNYR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by President Baumeler Alfred

    4 - Synergy CHC Corp. (0001562733) (Issuer)

    7/1/26 4:40:00 PM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    SEC Form 4 filed by Chief Financial Officer Fickett Jaime

    4 - Synergy CHC Corp. (0001562733) (Issuer)

    7/1/26 4:33:05 PM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    SEC Form 4 filed by CEO and Chairman Ross Jack

    4 - Synergy CHC Corp. (0001562733) (Issuer)

    7/1/26 4:15:32 PM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    $SNYR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D filed by Synergy CHC Corp.

    SC 13D - Synergy CHC Corp. (0001562733) (Subject)

    10/31/24 9:55:58 PM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    SEC Form SC 13G filed by Synergy CHC Corp.

    SC 13G - Synergy CHC Corp. (0001562733) (Subject)

    10/25/24 7:46:44 AM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    $SNYR
    Leadership Updates

    Live Leadership Updates

    View All

    Synergy CHC Corp. (NASDAQ: SNYR) Appoints Pedro Colmenares as Director of Sales & Marketing for Mexico & Latin America

    WESTBROOK, Maine, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ:SNYR) ("Synergy" or the "Company"), a leading consumer health and wellness company, today announced that Pedro Colmenares has been appointed Director of Sales & Marketing for Mexico & Latin America. In this role, Mr. Colmenares will lead commercial strategy, market expansion, and go-to-market execution across the region. Mr. Colmenares joins the Company at a pivotal time as it advances its international growth strategy. As announced in May 2025, Synergy established a wholly owned subsidiary in Mexico and has begun its initial market entry through shipments of its supplement products to Costco Mexico this week. A

    12/16/25 8:00:00 AM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    Synergy CHC (NASDAQ: SNYR) Taps Former Coca-Cola Executive to Lead Strategic Partnerships; Appoints Veteran Costco Buyer to Board of Directors

    Board member Scott Woodburn transitions to Head of Strategic Partnerships to accelerate FOCUSfactor Energy Drink expansion Former Costco Buyer Teresa Thompson brings nearly 40 years of retail expertise in vitamins and supplements WESTBROOK, Maine, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ:SNYR) ("Synergy" or the "Company"), a leading consumer health and wellness company, today announced two key leadership changes: Scott Woodburn has been appointed to Head of Strategic Partnerships to drive the Company's expansion in functional beverages, and Teresa Thompson has been appointed to Synergy's Board of Directors (the "Board"), effective immediately. In connection with Woodb

    9/22/25 8:00:00 AM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    Synergy CHC (NASDAQ: SNYR) Taps Former Coca-Cola Executive to Help Drive FOCUSfactor Energy Drink Global Expansion

    WESTBROOK, Maine, June 10, 2025 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ:SNYR) ("Synergy" or the "Company"), a fast-growing consumer health and wellness company, announced today that Damian Marano has been named Vice President of Beverage, effective immediately. This appointment marks a major milestone in the Company's aggressive push into the booming functional beverage market. "We're excited to welcome Damian to Synergy's executive leadership team," said Jack Ross, CEO of Synergy CHC Corp. "Damian's deep expertise in beverage, CPG, and technology-enabled growth adds another high-caliber industry veteran to further guide our beverage business through its next phase. His proven track

    6/10/25 8:00:00 AM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    $SNYR
    Financials

    Live finance-specific insights

    View All

    Synergy CHC Corp. Reports Fourth Quarter and Full Year 2025 Financial Results

    NORTH WINDHAM, Maine, April 01, 2026 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ:SNYR) ("Synergy" or the "Company"), a consumer health and wellness company, is announcing its financial results for the three and twelve months ended December 31, 2025. "Our full year results reflect a year of meaningful strategic progress and continued advancement of our priority growth initiatives," said Jack Ross, CEO of Synergy CHC Corp. "During 2026 on the beverage side, we have shipped our Focus and Energy RTDs and shots into several new key distribution partners, including EG America, Wakefern Food, and Pine State Beverage, to name a few. With millions of cans of RTDs and shots in stock and ready to

    4/1/26 8:00:00 AM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    Synergy CHC Corp. Announces Date Change of Fourth Quarter and Full Year 2025 Earnings and Conference Call

    WESTBROOK, Maine, March 30, 2026 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ:SNYR) ("Synergy" or the "Company"), a leading consumer health and wellness company, today announced an updated date for the release of its fourth quarter and full year financial results ended December 31, 2025. The Company will now report its financial results on Wednesday, April 1, 2026, before the open of market trading. In conjunction with reporting fourth quarter and full year 2025 results, Synergy will host a conference call at 9:00 a.m. ET / 6:00 a.m. PT with the Company's Chief Executive Officer, Jack Ross, and the Company's Chief Financial Officer, Jaime Fickett. A live webcast of the call will be avail

    3/30/26 5:14:41 PM ET
    $SNYR
    Other Pharmaceuticals
    Health Care

    Synergy CHC Corp. Announces Fourth Quarter and Full Year 2025 Earnings and Conference Call Information

    WESTBROOK, Maine, March 17, 2026 (GLOBE NEWSWIRE) -- Synergy CHC Corp. (NASDAQ:SNYR) ("Synergy" or the "Company"), a leading consumer health and wellness company, today announced that it plans to release financial results for the fourth quarter and full year ended December 31, 2025, on Tuesday, March 31, 2026, before the open of market trading. In conjunction with reporting fourth quarter and full year 2025 results, Synergy will host a conference call at 9:00 a.m. ET / 6:00 a.m. PT with the Company's Chief Executive Officer, Jack Ross, and the Company's Chief Financial Officer, Jaime Fickett. A live webcast of the call will be available on the Investor Relations section of Synergy's websi

    3/17/26 4:05:00 PM ET
    $SNYR
    Other Pharmaceuticals
    Health Care